Discovery of AZD0364, a potent and selective oral inhibitor of ERK1/2 that is efficacious in both monotherapy and combination therapy in models of NSCLC

被引：0

作者：

Simpson, Iain ^{[1
]}

Anderton, Mark J. ^{[1
]}

Andrews, David M. ^{[1
]}

Breed, Jason ^{[1
]}

Davies, Emma ^{[1
]}

Debreczeni, Judit E. ^{[1
]}

Flemington, Vikki ^{[1
]}

Gibbons, Francis D. ^{[2
]}

Graham, Mark A. ^{[1
]}

Hopcroft, Philip ^{[1
]}

Howard, Tina ^{[1
]}

Hudson, Julian ^{[1
]}

Jones, Clifford D. ^{[1
]}

Jones, Christopher ^{[1
]}

Lindsay, Nicola ^{[1
]}

Pease, J. Elizabeth ^{[1
]}

Rawlins, Philip ^{[1
]}

Roberts, Karen ^{[1
]}

Swallow, Steve ^{[1
]}

St-Gallay, Steve ^{[1
]}

Tonge, Michael E. ^{[1
]}

Ward, Richard A. ^{[1
]}

机构：

[1] AstraZeneca, Cambridge, England

[2] AstraZeneca, Boston, MA USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-1647

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1647

引用

页数：3

共 50 条

[1] Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)
Ward, Richard A.
Anderton, Mark J.
Bethel, Paul
Breed, Jason
Cook, Calum
Davies, Emma J.
Dobson, Andrew
Dong, Zhiqiang
Fairley, Gary
Farrington, Paul
Feron, Lyman
Flemington, Vikki
Gibbons, Francis D.
Graham, Mark A.
Greenwood, Ryan
Hanson, Lyndsey
Hopcroft, Philip
Howells, Rachel
Hudson, Julian
James, Michael
Jones, Clifford D.
Jones, Christopher R.
Li, Yongchao
Lamont, Scott
Lewis, Richard
Lindsay, Nicola
McCabe, James
McGuire, Thomas
Rawlins, Philip
Roberts, Karen
Sandin, Linda
Simpson, Iain
Swallow, Steve
Tang, Jia
Tomkinson, Gary
Tonge, Michael
Wang, Zhenhua
Zhai, Baochang
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (24) : 11004 - 11018
[2] AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Flemington, Vikki
Davies, Emma J.
Robinson, David
Sandin, Linda C.
Delpuech, Oona
Zhang, Pei
Hanson, Lyndsey
Farrington, Paul
Bell, Sigourney
Falenta, Katarzyna
Gibbons, Francis D.
Lindsay, Nicola
Smith, Aaron
Wilson, Joanne
Roberts, Karen
Tonge, Michael
Hopcroft, Philip
Willis, Sophie E.
Roudier, Martine P.
Rooney, Claire
Coker, Elizabeth A.
Jaaks, Patricia
Garnett, Mathew J.
Fawell, Stephen E.
Jones, Clifford D.
Ward, Richard A.
Simpson, Iain
Cosulich, Sabina C.
Pease, J. Elizabeth
Smith, Paul D.
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (02) : 238 - 249
[3] Combination of the novel ERK inhibitor AZD0364 with the MEK inhibitor selumetinib significantly enhances antitumor activity in KRAS mutant tumor models
Flemington, Vikki
Simpson, Iain
Breed, Jason
Davies, Emma
Gibbons, Francis
Hopcroft, Phillip
Lyndsay, Nicola
Jones, Christopher
Jones, Clifford
Robinson, David
Rooney, Claire
Roberts, Karen
Sandin, Linda
Ward, Richard
Zhang, Pei
Pease, Elizabeth
CANCER RESEARCH, 2018, 78 (13)
[4] Discovery of Highly Potent, Selective, and Efficacious Small Molecule Inhibitors of ERK1/2
Ren, Li
Grina, Jonas
Moreno, David
Blake, James F.
Gaudino, John J.
Garrey, Rustam
Metcalf, Andrew T.
Burkard, Michael
Martinson, Matthew
Rasor, Kevin
Chen, Huifen
Dean, Brian
Gould, Stephen E.
Pacheco, Patricia
Shahidi-Latham, Sheerin
Yin, Jianping
West, Kristina
Wang, Weiru
Moffat, John G.
Schwarz, Jacob B.
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (04) : 1976 - 1991
[5] Discovery and characterization of AZ6197, a potent and selective ERK1/2 inhibitor
Flemington, Vikki
Simpson, Iain
Davies, Emma
Robinson, David
Lindsay, Nicola
Hanson, Lyndsey
Hopcroft, Philip
Tonge, Michael
Roberts, Karen
Ward, Richard
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[6] Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development
Robarge, Kirk
Schwarz, Jacob
Blake, Jim
Burkard, Michael
Chan, Jocelyn
Chen, Huifen
Chou, Kang-Jye
Diaz, Dolores
Gaudino, John
Gould, Stephen
Grina, Jonas
Xin Linghu
Liu, Lichuan
Martinson, Matthew
Moreno, David A.
Orr, Christine
Pacheco, Patricia
Qin, Ann
Rasor, Kevin
Ren, Li
Shahidi-Latham, Sheerin
Stults, Jeffrey
Sullivan, Francis
Wang, Weiru
Yin, Peter
Zhou, Aihe
Belvin, Marcia
Merchant, Mark
Moffat, John G.
CANCER RESEARCH, 2014, 74 (19)
[7] Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development
Schwarz, Jacob
Blake, James
Burkard, Michael
Chan, Jocelyn
Chen, Huifen
Chou, Kang-Jye
Diaz, Dolores
Dudley, Danette
Gaudino, John
Gould, Stephen
Grina, Jonas
Hunsaker, Thomas
Liu, Lichuan
Martinson, Matthew
Moreno, David
Orr, Christine
Pacheco, Patricia
Qin, Ann
Rasor, Kevin
Ren, Li
Robarge, Kirk
Shahidi-Latham, Sheerin
Stults, Jeffrey
Sullivan, Francis
Wang, Weiru
Yin, Jianping
Zhou, Aihe
Belvin, Marcia
Merchant, Mark
Moffat, John
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
[8] Discovery of potent and selective inhibitors of ERK1/2 with a unique mechanism of action
Deng, Yongqi
Samatar, Ahmed
Shipps, Gerald
Cooper, Alan
Long, Brian
Carr, Donnar
Xiao, Li
Hruza, Alan
Wang, Tong
Zhu, Liang
Nan, Yang
Patel, Mehul
Muppalla, Kiran
Zhu, Hugh
Boga, Babu Sobhana
Gao, Xiaolei
CANCER RESEARCH, 2016, 76
[9] Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations
Bhagwat, Shripad V.
McMillen, William T.
Cai, Shufen
Zhao, Baohui
Whitesell, Matthew
Kindler, Lisa
Flack, Robert S.
Wu, Wenjuan
Huss, Karen
Anderson, Bryan
Yuan, Xiu-Juan
Jaken, Susan
McCann, Denis
Mathes, Brian
Dropsey, Andrew J.
Manro, Jason
Walgren, Jennie
Yuen, Eunice
Gong, Xueqian
Rodriguez, Michael J.
Huang, Jianping
Tiu, Ramon V.
Joseph, Sajan
Peng, Sheng-Bin
CANCER RESEARCH, 2017, 77
[10] The novel PARP1-selective inhibitor, AZD5305, is efficacious as monotherapy and in combination with standard of care chemotherapy in the in vivo preclinical models.
Staniszewska, Anna D.
Yates, James W.
Pike, Andy
Fazenbaker, Christine
Cook, Kimberly
Bosco, Emily
Smith, Aaron
Wilson, Joanne
Leo, Elisabetta
CANCER RESEARCH, 2021, 81 (13)

← 1 2 3 4 5 →